Corpus ID: 42367414

articleTriple antiplatelet therapy for preventing vascular events : a systematic review and meta-analysis

@inproceedings{Geeganage2015articleTripleAT,
  title={articleTriple antiplatelet therapy for preventing vascular events : a systematic review and meta-analysis},
  author={C. Geeganage and R. Wilcox and P. Bath},
  year={2015}
}
Background: Dual antiplatelet therapy is usually superior to mono therapy in preventing recurrent vascular events (VEs). This systematic review assesses the safety and efficacy of triple antiplatelet therapy in comparison with dual therapy in reducing recurrent vascular events. Methods: Completed randomized controlled trials investigating the effect of triple versus dual antiplatelet therapy in patients with ischaemic heart disease (IHD), cerebrovascular disease or peripheral vascular disease… CONTINUE READING

Figures and Tables from this paper.

References

SHOWING 1-10 OF 54 REFERENCES
Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query.
  • 25
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
  • 565